Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015

The prevalence of C. difficile infection (CDI) and severe CDI are influenced by the prevalence of specific C. difficile strains, which are themselves influenced by antimicrobial susceptibility determinants as well as antimicrobial usage patterns. Restriction endonuclease analysis (REA) typing and an...

Full description

Saved in:
Bibliographic Details
Published in:Anaerobe 2018-10, Vol.53, p.38-42
Main Authors: Cheknis, Adam, Johnson, Stuart, Chesnel, Laurent, Petrella, Laurica, Sambol, Susan, Dale, Suzanne E., Nary, Julia, Sears, Pamela, Citron, Diane M., Goldstein, Ellie J.C., Gerding, Dale N.
Format: Article
Language:English
Subjects:
Antimicrobial resistance
Antimicrobial susceptibility
Clostridioides difficile
Clostridium difficile
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3
cites cdi_FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3
container_end_page 42
container_issue
container_start_page 38
container_title Anaerobe
container_volume 53
creator Cheknis, Adam
Johnson, Stuart
Chesnel, Laurent
Petrella, Laurica
Sambol, Susan
Dale, Suzanne E.
Nary, Julia
Sears, Pamela
Citron, Diane M.
Goldstein, Ellie J.C.
Gerding, Dale N.
description The prevalence of C. difficile infection (CDI) and severe CDI are influenced by the prevalence of specific C. difficile strains, which are themselves influenced by antimicrobial susceptibility determinants as well as antimicrobial usage patterns. Restriction endonuclease analysis (REA) typing and antimicrobial susceptibility testing were used to characterize 1808 C. difficile isolates obtained from patients enrolled in four multicenter, multi-country, randomized CDI treatment trials conducted between 2006 and 2009 and between 2012 and 2015. By 2015, the epidemic REA group BI strain (RT027) had decreased in prevalence in North America (US: 43%–18%, Canada: 39%–24%, P 
doi_str_mv 10.1016/j.anaerobe.2018.05.009
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2053271811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1075996418300945</els_id><sourcerecordid>2053271811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3</originalsourceid><addsrcrecordid>eNqFUU1v1DAQjRCIlsJfqHwsEgljO47jG2hVPqQiDtCz5dhj8MqJFzup1H_DT8WrbXvlYs8bvzfjmdc0lxQ6CnR4v-_MYjCnCTsGdOxAdADqWXNOQYl2ZLJ_foylaJUa-rPmVSl7AEp7IV42Z0yN4wACzpu_31JEu0WTCR6CwzmkmH7dk-TJLqay5uBCqvlCrp7wNr8lLngfbIhIas6EpZCMNt1hRkd8TjOxMSzBmkiqxMRCwkLW30huf7wju_p1Z4hZHLnecjrgScEAhrYeiqypAsoqoOJ188JXPb55uC-a20_XP3df2pvvn7_uPt60lg_j2vK-V5JJZdBOjDNHperlZKXgnIoBLVKv0Kv6CMCoMRy5nOom3ehFDS2_aK5OdQ85_dmwrHoOxWKMZsG0Fc1AcCbpSGmlDieqzamUjF4fcphNvtcU9NEdvdeP7uijOxqErnNV4eVDj22a0T3JHu2ohA8nAtZJ7wJmXWzAxaILdb2rdin8r8c_dfCjCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2053271811</pqid></control><display><type>article</type><title>Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015</title><source>ScienceDirect Freedom Collection</source><creator>Cheknis, Adam ; Johnson, Stuart ; Chesnel, Laurent ; Petrella, Laurica ; Sambol, Susan ; Dale, Suzanne E. ; Nary, Julia ; Sears, Pamela ; Citron, Diane M. ; Goldstein, Ellie J.C. ; Gerding, Dale N.</creator><creatorcontrib>Cheknis, Adam ; Johnson, Stuart ; Chesnel, Laurent ; Petrella, Laurica ; Sambol, Susan ; Dale, Suzanne E. ; Nary, Julia ; Sears, Pamela ; Citron, Diane M. ; Goldstein, Ellie J.C. ; Gerding, Dale N.</creatorcontrib><description>The prevalence of C. difficile infection (CDI) and severe CDI are influenced by the prevalence of specific C. difficile strains, which are themselves influenced by antimicrobial susceptibility determinants as well as antimicrobial usage patterns. Restriction endonuclease analysis (REA) typing and antimicrobial susceptibility testing were used to characterize 1808 C. difficile isolates obtained from patients enrolled in four multicenter, multi-country, randomized CDI treatment trials conducted between 2006 and 2009 and between 2012 and 2015. By 2015, the epidemic REA group BI strain (RT027) had decreased in prevalence in North America (US: 43%–18%, Canada: 39%–24%, P &lt; 0.001), but rates of moxifloxacin resistance remained high. In contrast, REA group Y (RT014/020) and DH (RT106) strains, both of which had low rates of moxifloxacin resistance, increased in prevalence (Y strain - US: 6%–17%, Canada: 11%–23%, P &lt; 0.001; DH strain - US: 1%–11%, Canada: 0%–8%, P &lt; 0.0001). In Europe, the BI strain (RT027) was highly prevalent in Eastern European countries in 2015, but was unchanged in other parts of Europe. As in North America, the Y strain (RT014/020) was prevalent in both time periods, but the DH strain was rarely identified. Continued international molecular surveillance of C. difficile will be important to track prevalence of known epidemic strains and detect emergence of new strains of potential epidemiologic significance. •Epidemiology of C. difficile strains from multinational clinical trials is described.•Similar REA group strains were identified in North America and Europe.•REA group BI decreased in prevalence in North America between 2006 and 2015.•BI was prevalent in Eastern European Countries between 2012 and 2015.•An emerging strain, REA group DH, increased in North America between 2006 and 2015.</description><identifier>ISSN: 1075-9964</identifier><identifier>EISSN: 1095-8274</identifier><identifier>DOI: 10.1016/j.anaerobe.2018.05.009</identifier><identifier>PMID: 29886050</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antimicrobial resistance ; Antimicrobial susceptibility ; Clostridioides difficile ; Clostridium difficile</subject><ispartof>Anaerobe, 2018-10, Vol.53, p.38-42</ispartof><rights>2018</rights><rights>Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3</citedby><cites>FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29886050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheknis, Adam</creatorcontrib><creatorcontrib>Johnson, Stuart</creatorcontrib><creatorcontrib>Chesnel, Laurent</creatorcontrib><creatorcontrib>Petrella, Laurica</creatorcontrib><creatorcontrib>Sambol, Susan</creatorcontrib><creatorcontrib>Dale, Suzanne E.</creatorcontrib><creatorcontrib>Nary, Julia</creatorcontrib><creatorcontrib>Sears, Pamela</creatorcontrib><creatorcontrib>Citron, Diane M.</creatorcontrib><creatorcontrib>Goldstein, Ellie J.C.</creatorcontrib><creatorcontrib>Gerding, Dale N.</creatorcontrib><title>Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015</title><title>Anaerobe</title><addtitle>Anaerobe</addtitle><description>The prevalence of C. difficile infection (CDI) and severe CDI are influenced by the prevalence of specific C. difficile strains, which are themselves influenced by antimicrobial susceptibility determinants as well as antimicrobial usage patterns. Restriction endonuclease analysis (REA) typing and antimicrobial susceptibility testing were used to characterize 1808 C. difficile isolates obtained from patients enrolled in four multicenter, multi-country, randomized CDI treatment trials conducted between 2006 and 2009 and between 2012 and 2015. By 2015, the epidemic REA group BI strain (RT027) had decreased in prevalence in North America (US: 43%–18%, Canada: 39%–24%, P &lt; 0.001), but rates of moxifloxacin resistance remained high. In contrast, REA group Y (RT014/020) and DH (RT106) strains, both of which had low rates of moxifloxacin resistance, increased in prevalence (Y strain - US: 6%–17%, Canada: 11%–23%, P &lt; 0.001; DH strain - US: 1%–11%, Canada: 0%–8%, P &lt; 0.0001). In Europe, the BI strain (RT027) was highly prevalent in Eastern European countries in 2015, but was unchanged in other parts of Europe. As in North America, the Y strain (RT014/020) was prevalent in both time periods, but the DH strain was rarely identified. Continued international molecular surveillance of C. difficile will be important to track prevalence of known epidemic strains and detect emergence of new strains of potential epidemiologic significance. •Epidemiology of C. difficile strains from multinational clinical trials is described.•Similar REA group strains were identified in North America and Europe.•REA group BI decreased in prevalence in North America between 2006 and 2015.•BI was prevalent in Eastern European Countries between 2012 and 2015.•An emerging strain, REA group DH, increased in North America between 2006 and 2015.</description><subject>Antimicrobial resistance</subject><subject>Antimicrobial susceptibility</subject><subject>Clostridioides difficile</subject><subject>Clostridium difficile</subject><issn>1075-9964</issn><issn>1095-8274</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFUU1v1DAQjRCIlsJfqHwsEgljO47jG2hVPqQiDtCz5dhj8MqJFzup1H_DT8WrbXvlYs8bvzfjmdc0lxQ6CnR4v-_MYjCnCTsGdOxAdADqWXNOQYl2ZLJ_foylaJUa-rPmVSl7AEp7IV42Z0yN4wACzpu_31JEu0WTCR6CwzmkmH7dk-TJLqay5uBCqvlCrp7wNr8lLngfbIhIas6EpZCMNt1hRkd8TjOxMSzBmkiqxMRCwkLW30huf7wju_p1Z4hZHLnecjrgScEAhrYeiqypAsoqoOJ188JXPb55uC-a20_XP3df2pvvn7_uPt60lg_j2vK-V5JJZdBOjDNHperlZKXgnIoBLVKv0Kv6CMCoMRy5nOom3ehFDS2_aK5OdQ85_dmwrHoOxWKMZsG0Fc1AcCbpSGmlDieqzamUjF4fcphNvtcU9NEdvdeP7uijOxqErnNV4eVDj22a0T3JHu2ohA8nAtZJ7wJmXWzAxaILdb2rdin8r8c_dfCjCw</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Cheknis, Adam</creator><creator>Johnson, Stuart</creator><creator>Chesnel, Laurent</creator><creator>Petrella, Laurica</creator><creator>Sambol, Susan</creator><creator>Dale, Suzanne E.</creator><creator>Nary, Julia</creator><creator>Sears, Pamela</creator><creator>Citron, Diane M.</creator><creator>Goldstein, Ellie J.C.</creator><creator>Gerding, Dale N.</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201810</creationdate><title>Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015</title><author>Cheknis, Adam ; Johnson, Stuart ; Chesnel, Laurent ; Petrella, Laurica ; Sambol, Susan ; Dale, Suzanne E. ; Nary, Julia ; Sears, Pamela ; Citron, Diane M. ; Goldstein, Ellie J.C. ; Gerding, Dale N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antimicrobial resistance</topic><topic>Antimicrobial susceptibility</topic><topic>Clostridioides difficile</topic><topic>Clostridium difficile</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheknis, Adam</creatorcontrib><creatorcontrib>Johnson, Stuart</creatorcontrib><creatorcontrib>Chesnel, Laurent</creatorcontrib><creatorcontrib>Petrella, Laurica</creatorcontrib><creatorcontrib>Sambol, Susan</creatorcontrib><creatorcontrib>Dale, Suzanne E.</creatorcontrib><creatorcontrib>Nary, Julia</creatorcontrib><creatorcontrib>Sears, Pamela</creatorcontrib><creatorcontrib>Citron, Diane M.</creatorcontrib><creatorcontrib>Goldstein, Ellie J.C.</creatorcontrib><creatorcontrib>Gerding, Dale N.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anaerobe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheknis, Adam</au><au>Johnson, Stuart</au><au>Chesnel, Laurent</au><au>Petrella, Laurica</au><au>Sambol, Susan</au><au>Dale, Suzanne E.</au><au>Nary, Julia</au><au>Sears, Pamela</au><au>Citron, Diane M.</au><au>Goldstein, Ellie J.C.</au><au>Gerding, Dale N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015</atitle><jtitle>Anaerobe</jtitle><addtitle>Anaerobe</addtitle><date>2018-10</date><risdate>2018</risdate><volume>53</volume><spage>38</spage><epage>42</epage><pages>38-42</pages><issn>1075-9964</issn><eissn>1095-8274</eissn><abstract>The prevalence of C. difficile infection (CDI) and severe CDI are influenced by the prevalence of specific C. difficile strains, which are themselves influenced by antimicrobial susceptibility determinants as well as antimicrobial usage patterns. Restriction endonuclease analysis (REA) typing and antimicrobial susceptibility testing were used to characterize 1808 C. difficile isolates obtained from patients enrolled in four multicenter, multi-country, randomized CDI treatment trials conducted between 2006 and 2009 and between 2012 and 2015. By 2015, the epidemic REA group BI strain (RT027) had decreased in prevalence in North America (US: 43%–18%, Canada: 39%–24%, P &lt; 0.001), but rates of moxifloxacin resistance remained high. In contrast, REA group Y (RT014/020) and DH (RT106) strains, both of which had low rates of moxifloxacin resistance, increased in prevalence (Y strain - US: 6%–17%, Canada: 11%–23%, P &lt; 0.001; DH strain - US: 1%–11%, Canada: 0%–8%, P &lt; 0.0001). In Europe, the BI strain (RT027) was highly prevalent in Eastern European countries in 2015, but was unchanged in other parts of Europe. As in North America, the Y strain (RT014/020) was prevalent in both time periods, but the DH strain was rarely identified. Continued international molecular surveillance of C. difficile will be important to track prevalence of known epidemic strains and detect emergence of new strains of potential epidemiologic significance. •Epidemiology of C. difficile strains from multinational clinical trials is described.•Similar REA group strains were identified in North America and Europe.•REA group BI decreased in prevalence in North America between 2006 and 2015.•BI was prevalent in Eastern European Countries between 2012 and 2015.•An emerging strain, REA group DH, increased in North America between 2006 and 2015.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29886050</pmid><doi>10.1016/j.anaerobe.2018.05.009</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1075-9964
ispartof Anaerobe, 2018-10, Vol.53, p.38-42
issn 1075-9964
1095-8274
language eng
recordid cdi_proquest_miscellaneous_2053271811
source ScienceDirect Freedom Collection
subjects Antimicrobial resistance
Antimicrobial susceptibility
Clostridioides difficile
Clostridium difficile
title Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A37%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20epidemiology%20of%20Clostridioides%20(Clostridium)%20difficile%20strains%20recovered%20from%20clinical%20trials%20in%20the%20US,%20Canada%20and%20Europe%20from%202006-2009%20to%202012-2015&rft.jtitle=Anaerobe&rft.au=Cheknis,%20Adam&rft.date=2018-10&rft.volume=53&rft.spage=38&rft.epage=42&rft.pages=38-42&rft.issn=1075-9964&rft.eissn=1095-8274&rft_id=info:doi/10.1016/j.anaerobe.2018.05.009&rft_dat=%3Cproquest_cross%3E2053271811%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c368t-34497279aecb232d17947bc7533156ece1f9ef9cb20021aa3e37b101d8f5e37c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2053271811&rft_id=info:pmid/29886050&rfr_iscdi=true